Paradigm Financial Advisors’s Maravai LifeSciences MRVI Stock Holding History

Paradigm Financial Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$442K	Sell	10,540 -865	-8%	-$35K	0.1%	130
2021 Q3	$560K	Sell	11,405 -715	-6%	-$34.9K	0.13%	105
2021 Q2	$506K	Sell	12,120 -900	-7%	-$34.9K	0.11%	115
2021 Q1	$464K	Hold	13,020	–	–	0.11%	121
2020 Q4	$365K	Buy	+13,020	New	+$363K	0.1%	119

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Paradigm Financial Advisors's MRVI Position: Q4 2021 in Review

Paradigm Financial Advisors reduced its Maravai LifeSciences (MRVI) stake by 7.6% in Q4 2021, selling an estimated $35K and leaving 10,540 shares worth $442K. The position accounts for 0.1% of the portfolio, ranked #130.

Paradigm Financial Advisors first reported a position in MRVI in Q4 2020 and has held it in 5 quarters since. The position peaked at $560K in Q3 2021. 229 funds tracked by Wall St. Rank hold MRVI as of Q4 2021.

Paradigm Financial Advisors held 10,540 shares of Maravai LifeSciences worth $442K as of Q4 2021.
Paradigm Financial Advisors sold 865 Maravai LifeSciences shares in Q4 2021, an estimated $35K.
Maravai LifeSciences made up 0.1% of Paradigm Financial Advisors's portfolio in Q4 2021, its #130 holding.
Paradigm Financial Advisors first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 5 quarters since.
Paradigm Financial Advisors's Maravai LifeSciences position peaked at $560K in Q3 2021.
229 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2021.

Based on Paradigm Financial Advisors's 13F filing for Q4 2021, filed 10 Feb 2022.